Preformulation Studies of Pantoprazole: Fundamental Part of Formulation Design

Abstract

Once the novel molecule is planted, preformulation study is one of the fractions that is started. In a larger sense, it covers with research on a molecule's physical, chemical, analytical, and medicinal properties and offers suggestions for effective modifications that could be made to improve performance. The study of preformulation factors can contribute to the development of pharmaceutical formulations that are dependable, safe, stable, and efficacious. Pantoprazole is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion. PPIs, pantoprazole binds to the proton pump (H+,K+ -adenosine triphosphatase) in the parietal cells to exercise its pharmacodynamic effects; however, in comparison to other PPIs, its binding may be more specific for the proton pump. When given as an enteric-coated, delayed-release tablet, pantoprazole is well absorbed and has a 77 % oral bioavailability. It is metabolized by the liver's cytochrome P2C19 into the inactive metabolite hydroxypantoprazole, which is then subjected to sulphate conjugation. Independent of dose, the elimination half-life ranges from 0.9 to 1.9 hours. Similar to other PPIs, pantoprazole is effective in promoting the healing of gastric and duodenal ulcers. In the present works overall objective of preformulation studies of Pantoprazole is to engender information useful in developing stable and Bioavailable dosage forms.